Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Wang, Xuanyi; Faisal Mahmood, Syed; Jin, Fang; Kooi Cheah, Wee; Ahmad, M.; Amjad Sohail, Mian; Waheed, Ahmad; Kumar L Suppan, Vijaya; Ahsan Sayeed, Muneeba; Luxmi, Shobha; Teo, Aik-Howe; Yuan Lee, Li; Qi, Yangyang; Pei, Rongjuan; Deng, Wei; Xu, Zhong-Hui; Yang, Jiaming; Zhang, Yan; Guan, Wuxiang; Yu, Xiong

doi:10.1080/22221751.2022.2088406

Public

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Published in Emerging Microbes & Infections • Jun 10, 2022

Authors:

Xuanyi Wang

Syed Faisal Mahmood

Fang Jin

Abstract

Waning of neutralizing titres along with decline of protection efficacy after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose of a recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vacc...

Subject

Virology

Medicine

Heterologous

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!